Study of Oral LBH589 in Adult Participants With Refractory/Resistant Cutaneous T-Cell Lymphoma (CTCL)
- First Posted Date
- 2007-06-25
- Last Posted Date
- 2021-08-18
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 9
- Registration Number
- NCT00490776
- Locations
- 🇺🇸
Rush Presbyterian Hospital/St. Luke's Medical Center, Chicago, Illinois, United States
🇺🇸UCLA Medical Center School of Medicine/ Dpt of Hematology-Oncology, Los Angeles, California, United States
🇺🇸Florida Academic Dermatology Centers, Miami, Florida, United States
ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D
- First Posted Date
- 2007-06-22
- Last Posted Date
- 2025-03-21
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 8381
- Registration Number
- NCT00490139
- Locations
- 🇬🇧
Novartis Investigative Site, Worthing, United Kingdom
Acetaminophen or Fluvastatin Compared to Placebo on the Transient Post-Dose Symptoms (PDS) Following an Intravenous (i.v.) Infusion of a Single Dose of Zoledronic Acid 5mg, in Post-menopausal Women With Low Bone Mass
- Conditions
- Osteoporosis
- Interventions
- First Posted Date
- 2007-06-21
- Last Posted Date
- 2011-02-18
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 793
- Registration Number
- NCT00489424
- Locations
- 🇺🇸
Refer to the E-portal link for ZOL446HUS136, Http://www.osteoporosisclinicalresearch.com, New Jersey, United States
Safety, Efficacy, Pharmacokinetics, Pharmacodynamics of ACZ885 in Patients With NALP3 Mutations and Clinical Symptoms
- First Posted Date
- 2007-06-19
- Last Posted Date
- 2009-02-17
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 34
- Registration Number
- NCT00487708
- Locations
- 🇩🇪
Novartis investigative site, Nuernberg, Germany
🇪🇸Novartis Investigator Site, Oviedo, Spain
🇬🇧Novartis Investigative site, London, United Kingdom
Efficacy and Safety of Deferasirox in Patients With Myelodysplastic Syndrome and Transfusion-dependent Iron Overload
- Conditions
- Myelodysplastic SyndromesTransfusion Dependent Iron Overload
- Interventions
- Drug: ICL670/Deferasirox
- First Posted Date
- 2007-06-01
- Last Posted Date
- 2017-05-31
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 63
- Registration Number
- NCT00481143
- Locations
- 🇩🇪
Novartis Investigative Site, Berlin, Germany
A Phase 1 Study Investigating the Combination of RAD001, Cetuximab and Irinotecan as Second-line Therapy After FOLFOX (or XELOX) Plus Bevacizumab in Patients With Metastatic Colorectal Cancer
- Conditions
- Colorectal CancerColorectal CarcinomaColorectal TumorsNeoplasms, Colorectal
- Interventions
- Drug: RAD001, Cetuximab, Irinotecan
- First Posted Date
- 2007-05-25
- Last Posted Date
- 2012-11-02
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 19
- Registration Number
- NCT00478634
- Locations
- 🇺🇸
UCSD - Moores Cancer Center, La Jolla, California, United States
🇺🇸Highlands Oncology Group, Fayetteville, Arkansas, United States
🇺🇸Cancer Care Associates Medical Group, Inc., Redondo Beach, California, United States
Safety and Efficacy of Imatinib Mesylate in Patients With Pulmonary Arterial Hypertension
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Drug: Placebo
- First Posted Date
- 2007-05-23
- Last Posted Date
- 2015-03-23
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 59
- Registration Number
- NCT00477269
- Locations
- 🇺🇸
Novartis investigative site, Newark, New Jersey, United States
🇬🇧Novartis Investigative Site, Glasgow, United Kingdom
🇬🇧Novartis Investigative site, Papworth, United Kingdom
A Study to Determine the Absorption, Distribution, Metabolism, and Excretion of LBH589
- Conditions
- Cancer Patients With Advanced Solid Tumors Including Lymphoma or Chronic Hematological Malignancies
- Interventions
- First Posted Date
- 2007-05-11
- Last Posted Date
- 2012-05-01
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 4
- Registration Number
- NCT00472368
- Locations
- 🇺🇸
Novartis Investigative Site, Buffalo, New York, United States
A Study of Imatinib Versus Nilotinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
- First Posted Date
- 2007-05-10
- Last Posted Date
- 2020-11-18
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 846
- Registration Number
- NCT00471497
- Locations
- 🇺🇸
University of California at Los Angeles Dept. of Hematology Clinic, Los Angeles, California, United States
🇺🇸Kaiser Permanente - California Northern Kaiser Med, Vallejo, California, United States
🇺🇸Florida Cancer Specialists Dept. FloridaCancerSpecialists, Fort Myers, Florida, United States
Efficacy and Safety of Nilotinib (AMN107) Compared With Current Treatment Options in Patients With GIST Who Have Failed Both Imatinib and Sunitinib
- Conditions
- Gastrointestinal Stromal Tumors
- Interventions
- Other: Best Supportive Care (BSC) +/- imatinib or sunitinib
- First Posted Date
- 2007-05-09
- Last Posted Date
- 2012-06-12
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 248
- Registration Number
- NCT00471328
- Locations
- 🇺🇸
Washington University School of Medicine - Siteman Cancer Center, St. Louis, Missouri, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸University of Texas/MD Anderson Cancer Center, Houston, Texas, United States